

Core operating trend remains soft

BFSI - NBFCs ▶ Result Update ▶ August 01, 2026

CMP (Rs): 523 | TP (Rs): 580

LICHF reported a subdued quarter, with muted AUM growth (~4% yoy) and continued margin compression, even as PAT grew 9.4% yoy to ~Rs14.88bn, aided by NPA recoveries. NIM compression of ~10bps yoy to 2.58% was mainly due to past PLR cuts and rising competitive pricing. The management's strategies to improve margins include diversification into non-individual home loans (LAP and LRD segments), which offer ~150bps higher yields than HL, and inorganic growth through direct assignment and co-lending. Overall asset quality is stable, while credit cost remained negative in 1Q (-14bps), driven by recoveries from written-off accounts, an ARC portfolio sale, and an accounting reclassification of recoveries under the impairment head. The management remained confident of modest 8-10% AUM growth for FY27, while expecting full-year disbursements to grow 10-12% (~15% in 2Q) and credit costs of 10-15bps. Factoring in the 1Q performance and the structurally weak growth, margin outlook, and credit cost guidance, we adjust our FY27-29 estimates while leaving our FY28-29 earnings estimate largely unchanged. We reiterate ADD and Jun-27E TP of Rs580, implying an FY28E PBV of 0.6x.

Recoveries support earnings; growth and margins under pressure

LICHF reported 1QFY27 disbursements of Rs150.14bn, up 14.5% yoy, while PAT grew 9.4% yoy to Rs14.88bn. AUM stood at Rs3.22trn, registering 4.0% yoy growth. Reported NIM compressed 10bps yoy to 2.58%, while COF stood at 7.28% and the annualized yield came in at 9.12% (with incremental disbursement yield lower at 8.25%). ROA improved 9bps yoy to 1.85%, while ROE stood at 14%. Operating expenses were slightly elevated due to a Rs220mn one-off gratuity provision, and credit costs stood at -14bps. Asset quality improved, with GS3 at 2.14% (down 48bps yoy) and PCR at 48%.

Growth aspirations intact; strategic mix shift to support margins

The management remains confident of 8-10% AUM growth in FY27, with full-year disbursements of 10-12%, as efforts to regain business momentum gain traction. The management indicated that while intense pricing competition in the core HL segment may cap NIM around 2.6% (earlier guidance of 2.6-2.7%), overall COF is likely to be broadly stable. To offset margin pressure, the company is progressing well on its strategic initiatives, deliberately shifting its focus toward higher-yielding non-housing individual loans (like LAP and LRD) and rolling out DA and co-lending policies. Additionally, plans to establish a dedicated affordable housing vertical are underway as a future growth lever, though the initiative currently remains a work-in-progress, pending board and committee approvals. These efforts, backed by new digital tools and automated loan processing to boost employee productivity, are expected to improve operating efficiency, while credit cost is likely to remain well-contained at 10-15bps; overall, the company targets steady profitability and improving asset quality for the full year.

Factoring in 1Q performance; maintain ADD and Jun27E TP of Rs580

Factoring in the softer 1QFY27 performance and management commentary, we adjust our estimates while leaving our FY28-29E earnings largely unchanged (Exhibit 2). We maintain ADD with an unchanged Jun-27E TP of Rs580, implying an FY28E PBV of 0.6x.

LIC Housing Finance: Financial Snapshot (Consolidated)

Y/E 2026 (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Net profits	54,290	55,952	59,394	62,944	67,834
AUM growth (%)	7.3	4.2	6.2	8.0	9.3
NII growth (%)	(6.2)	4.4	6.4	8.9	9.0
NIMs (%)	2.7	2.7	2.7	2.8	2.8
PPOP growth (%)	(7.2)	7.3	1.6	8.4	8.3
Adj. EPS (Rs)	98.6	101.7	107.9	114.4	123.2
Adj. EPS growth (%)	13.9	3.1	6.2	6.0	7.8
Adj. BV (INR)	658.7	750.8	842.6	934.0	1,026.5
Adj. BVPS growth (%)	15.5	14.0	12.2	10.9	9.9
RoA (%)	1.8	1.8	1.8	1.8	1.8
RoE (%)	16.0	14.4	13.5	12.9	12.6
P/E (x)	5.3	5.1	4.8	4.6	4.2
P/ABV (x)	0.8	0.7	0.6	0.6	0.5

Source: Company, Emkay Research

Target Price – 12M	Jun-27
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	10.9

Stock Data	LICHF IN
52-week High (Rs)	598
52-week Low (Rs)	459
Shares outstanding (mn)	550.1
Market-cap (Rs bn)	288
Market-cap (USD mn)	3,016
Net-debt, FY27E (Rs mn)	NA
ADTV-3M (mn shares)	1.8
ADTV-3M (Rs mn)	897.4
ADTV-3M (USD mn)	9.4
Free float (%)	0.0
Nifty-50	24,383.6
INR/USD	95.4


Shareholding, Jun-26

Promoters (%)	45.2
FPIs/MFs (%)	21.5/21.0

Price Performance

(%)	1M	3M	12M
Absolute	(7.3)	(5.7)	(10.7)
Rel. to Nifty	(9.2)	(7.2)	(9.3)

1-Year share price trend (Rs)



Avinash Singh

avinash.singh@emkayglobal.com
+91-22-66121327

Kishan Rungta

kishan.rungta@emkayglobal.com
+91-22-66242490

Exhibit 1: Quarterly earnings snapshot

(Rs mn)	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	yoy (%)	qoq (%)
AUM	3,095,870	3,118,160	3,142,680	3,207,070	3,220,980	4.0%	0.4%
Disbursement	131,160	163,130	160,960	210,190	150,140	14.5%	-28.6%
NII	20,647	20,447	21,047	22,218	20,755	1%	-7%
Total income	21,211	21,747	22,449	22,895	21,175	0%	-8%
Opex	2,928	3,018	3,488	3,889	3,401	16%	-13%
PPOP	18,283	18,729	18,961	19,006	17,774	-3%	-6%
Provision	1,292	1,682	1,536	-337	-1,111	-186%	230%
PBT	16,991	17,047	17,425	19,342	18,884	11%	-2%
PAT	13,599	13,539	13,840	14,974	14,883	9%	-1%
Yield (reported)	9.60%	9.40%	9.33%	9.21%	9.12%	-48bps	-9bps
COF (reported)	7.50%	7.42%	7.28%	7.27%	7.28%	-22bps	1bps
NIMs (reported)	2.68%	2.62%	2.69%	2.80%	2.58%	-10bps	-22bps
Opex to AUM	0.38%	0.39%	0.45%	0.49%	0.42%	4bps	-7bps
Asset quality							
Credit cost	0.17%	0.22%	0.20%	-0.04%	-0.14%	-31bps	-10bps
GS3	2.62%	2.51%	2.45%	2.16%	2.14%	-48bps	-2bps
NS3	1.31%	1.19%	1.13%	1.09%	1.12%	-18bps	3bps
PCR	50.83%	53.11%	54.54%	49.98%	48.15%	-268bps	-183bps

Source: Company, Emkay Research

Exhibit 2: Change in estimates

Y/e Mar (Rs mn)	FY27E			FY28E			FY29E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
AUM	3,407,064	3,407,064	0.0%	3,677,935	3,677,935	0.0%	4,019,070	4,019,070	0.0%
Loan book growth	6.24%	6.24%	0bps	7.95%	7.95%	0bps	9.28%	9.28%	0bps
Net interest income	90,485	90,485	0.0%	98,559	98,559	0.0%	107,443	107,443	0.0%
Total income	95,805	92,578	-3.4%	104,293	101,258	-2.9%	113,657	110,883	-2.4%
PPOP	80,897	77,916	-3.7%	87,248	84,461	-3.2%	94,007	91,472	-2.7%
Provisions	6,888	2,753	-60.0%	7,768	4,805	-38.1%	8,884	5,629	-36.6%
PBT	74,009	75,163	1.6%	79,480	79,655	0.2%	85,123	85,843	0.8%
PAT	58,483	59,394	1.6%	62,806	62,944	0.2%	67,264	67,834	0.8%
EPS (Rs)	106.3	107.9	1.6%	114.1	114.4	0.2%	122.2	123.2	0.8%
BVPS (Rs)	841	843	0.2%	932	934	0.2%	1,024	1,026	0.2%
Net worth	462,966	463,741	0.17%	513,210	514,096	0.17%	563,659	564,971	0.23%
NIMs	2.74%	2.74%	0bps	2.78%	2.78%	0bps	2.79%	2.79%	0bps
NIM + Fees	2.90%	2.80%	-10bps	2.94%	2.86%	-9bps	2.95%	2.88%	-7bps
Cost-to-Income	15.56%	15.84%	28bps	16.34%	16.59%	25bps	17.29%	17.51%	22bps
Opex-to-AUM	0.45%	0.44%	-1bps	0.48%	0.47%	-1bps	0.51%	0.50%	-1bps
Credit costs	0.21%	0.08%	-13bps	0.22%	0.14%	-8bps	0.23%	0.15%	-8bps
GS3	2.09%	2.09%	0bps	2.03%	2.03%	0bps	1.98%	1.98%	0bps
NS3	1.04%	1.10%	6bps	0.99%	1.06%	8bps	0.96%	1.03%	7bps
PCR	51.00%	48.00%	-300bps	52.00%	48.20%	-380bps	52.00%	48.50%	-350bps
ROA	1.75%	1.78%	3bps	1.76%	1.76%	0bps	1.74%	1.75%	1bps
ROE	13.35%	13.54%	20bps	12.87%	12.87%	1bps	12.49%	12.57%	8bps

Source: Company, Emkay Research


Exhibit 3: Valuation metrics

	Price	Upside	PBV (x)			PER (x)			ROA (%)			ROE (%)			Book Value (Rs/sh)			EPS (Rs)		
			FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
At CMP	523	11%	0.62	0.56	0.5	4.8	4.6	4.2	1.8	1.8	1.8	13.5	12.9	12.6	843	934	1,026	107.9	114.4	123.2
AT TP	580		0.7	0.62	0.6	5.4	5.1	4.7	2.0	2.0	2.0	15.0	14.4	14.0	934	1,026	1,118	123.2	132.0	140.8

Source: Company, Emkay Research


Results in charts

Exhibit 4: AUM growth remains soft (4% yoy)




Source: Company, Emkay Research

Exhibit 5: Disbursement grew 14.5% yoy, broadly in line with management guidance




Source: Company, Emkay Research

Exhibit 6: Yield compression led by increasing competition and PLR cuts, while COF remains broadly steady




Source: Company, Emkay Research

Exhibit 7: Margins continue to see compression




Source: Company, Emkay Research

Exhibit 8: Opex ratio remained range-bound



Source: Company, Emkay Research


Exhibit 9: Change in recognition of NPA recovery drove negative credit cost



Source: Company, Emkay Research


This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

Exhibit 10: Asset quality stable



Source: Company, Emkay Research

Exhibit 11: ROE stable sequentially




Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)


Story in charts

Exhibit 12: AUM growth recovery to be gradual over FY27-29E




Source: Company, Emkay Research

Exhibit 13: Disbursement to improve as the affordable and NHL segments scale




Source: Company, Emkay Research

Exhibit 14: Yields to hold up as the share of high-yield products increases




Source: Company, Emkay Research

Exhibit 15: Changing mix resulting in margin improvement




Source: Company, Emkay Research

Exhibit 16: Opex to increase marginally as LICHF builds affordable infrastructure and invests in IT infrastructure



Source: Company, Emkay Research


Exhibit 17: Credit cost to be contained at under 15bps



Source: Company, Emkay Research


This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

Exhibit 18: Asset quality to be stable



Source: Company, Emkay Research

Exhibit 19: Deleveraging resulting in ROE moderation



Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Earnings call highlight

- The company reported a steady 1QFY27, with the outstanding loan portfolio growing 4% to Rs3.22trn. Total disbursements for the quarter were robust at Rs150.bn, marking 14.5% yoy growth, in line with the company's 15% 1Q guidance. PAT stood at Rs 14.9bn, up 9.4% yoy.
- NIM for 1Q stood at 2.58%, marginally below the guided 2.6% mark, primarily due to competitive pressures and previous rate cuts. Incremental disbursement yield was 8.25% vs cumulative portfolio yield of 9.12%. To protect and improve margins, the management is focusing on diversifying the portfolio toward higher-yielding non-housing individual loans (LAP and LRD), which offer an additional 150bps and grew 20% during the quarter.
- COF was stable at 7.28%, down 22bps yoy due to a diversified borrowing profile. The incremental cost of borrowing for the quarter was exceptionally competitive at 7.06%. The company expects Rs170bn of borrowings to mature this year at an average cost of 7.38%, likely to be refinanced at lower rates; consequently, the management expects the cumulative COF to increase by a maximum of only 3-4bps.
- The developer finance segment witnessed a strong start, with 1Q disbursements of Rs8.72bn (up 459% yoy on a low base). The company is actively targeting Rs40bn-Rs80bn in disbursements for this segment in FY27 (ATS ranging from as low as 250mn to as high as Rs2-3bn). The management is maintaining a cautious approach, aiming for yields around 10.5% and intentionally passing on top-tier builders who demand sub-8% rates.
- Asset quality improved, with Stage 3 exposure dropping to 2.14% from 2.62% yoy. The granular breakup of Stage 3 Assets (EAD) is as follows: Individual Home Loans (IHL) at 1.09% (Rs29.67bn); Non-Housing Individual (NHI) at 3.06% (Rs11.13bn); and Project/NHC at 20.53% (Rs28.19bn)
- The quarter saw strong NPA recoveries of Rs5.40bn, which included the sale of a Rs1.8bn stressed asset to ARC for a cash consideration of Rs1.4bn. A P/L reversal of Rs1.64bn comprised Rs1.32bn from ECL reversal and Rs0.32bn from direct recovery. An upgrade of a large Rs5bn restructured account is pending auditor alignment and is expected to be part of 2Q or 3Q income statement. Further, from a legacy technically written-off pool of ~Rs30bn, the management expects Rs5-6bn in recoveries this year and ~Rs20bn over the next two years.
- BT-out pressures persist as a regular course of business, with 1Q witnessing a gross BT-out of Rs30bn against BT-in of Rs15bn (net BT-out: Rs15bn). To counter this, the management has introduced a flexible retention strategy specifically tailored to negotiate with and retain prime, big-ticket customers.
- Operating expenses rose yoy, primarily due to a one-off gratuity provision of Rs220mn driven by an increase in G-Sec yields. Significant IT expenditure is planned for 2Q and 3Q to further tech capabilities.
- The STP channel via the HOMY app executed Rs9.6bn in disbursements. A data lakehouse project aimed at consolidating data for AI-driven lead generation and Early Warning Systems (EWS) is finalizing vendor selection.
- Other strategic initiatives include a direct assignment and co-lending policy currently in its final stages, expected to launch in 2Q to support both AUM growth and margins. Separately, plans to build an external team for the affordable housing business remain a work in progress, pending Board and NRC approvals.
- **Guidance**
 - Disbursement growth for 2Q is targeted at 15%.
 - Full-year AUM growth is guided at 8-10%.
 - Full-year disbursement growth is guided at 10-12%.
 - NIM is expected to be maintained ~2.6%.
 - Full-year credit cost is guided at 10-15bps.

This report is intended for Team White Marquis Solutions. For more information, please contact team.emkay@whitemarquesolutions.com

LIC Housing Finance: Consolidated Financials and Valuations

Profit & Loss					
Y/E 2026 (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Interest Income	276,713	282,757	294,287	313,466	338,619
Interest Expense	195,320	197,752	203,802	214,907	231,176
Net interest income	81,394	85,006	90,485	98,559	107,443
NII growth (%)	(6.2)	4.4	6.4	8.9	9.0
Non interest income	3,849	4,959	2,093	2,699	3,441
Total income	85,243	89,965	92,578	101,258	110,883
Operating expenses	13,826	13,302	14,661	16,798	19,411
PPOP	71,416	76,663	77,916	84,461	91,472
PPOP growth (%)	(7.2)	7.3	1.6	8.4	8.3
Provisions & contingencies	2,858	5,857	2,753	4,805	5,629
PBT	68,558	70,806	75,163	79,655	85,843
Extraordinary items	-	-	-	-	-
Tax expense	14,268	14,855	15,769	16,711	18,009
Minority interest	-	-	-	-	-
Income from JV/Associates	-	-	-	-	-
Reported PAT	54,290	55,952	59,394	62,944	67,834
PAT growth (%)	13.9	3.1	6.2	6.0	7.8
Adjusted PAT	54,290	55,952	59,394	62,944	67,834
Diluted EPS (Rs)	98.6	101.7	107.9	114.4	123.2
Diluted EPS growth (%)	13.9	3.1	6.2	6.0	7.8
DPS (Rs)	10.0	10.0	16.2	22.9	30.8
Dividend payout (%)	10.1	9.8	15.0	20.0	25.0
Effective tax rate (%)	20.8	21.0	21.0	21.0	21.0
Net interest margins (%)	2.7	2.7	2.7	2.8	2.8
Cost-income ratio (%)	16.2	14.8	15.8	16.6	17.5
PAT/PPOP (%)	76.0	73.0	76.2	74.5	74.2
Shares outstanding (mn)	550.4	550.4	550.4	550.4	550.4

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E 2026 (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Asset quality					
GNPL - Stage 3	76,010	69,273	71,171	74,585	79,387
NNPL - Stage 3	37,071	34,649	37,009	38,635	40,885
GNPL ratio - Stage 3 (%)	2.5	2.2	2.1	2.0	2.0
NNPL ratio - Stage 3 (%)	1.2	1.1	1.1	1.1	1.0
ECL coverage - Stage 3 (%)	51.2	50.0	48.0	48.2	48.5
ECL coverage - 1 & 2 (%)	1.6	1.4	1.4	1.3	1.3
Gross slippage - Stage 3	-	-	-	-	-
Gross slippage ratio (%)	-	-	-	-	-
Write-off ratio (%)	-	-	-	-	-
Total credit costs (%)	0.1	0.2	0.1	0.1	0.1
NNPA to networth (%)	10.2	8.4	8.0	7.5	7.2
Capital adequacy					
Total CAR (%)	21.5	24.2	24.7	25.4	25.5
Tier-1 (%)	20.0	22.8	23.2	23.9	24.1
Miscellaneous					
Total income growth (%)	(3.6)	5.5	2.9	9.4	9.5
Opex growth (%)	20.6	(3.8)	10.2	14.6	15.6
PPOP margin (%)	2.4	2.4	2.4	2.4	2.4
Credit costs-to-PPOP (%)	4.0	7.6	3.5	5.7	6.2
Loan-to-Assets (%)	95.1	95.8	96.2	96.6	96.7
Yield on loans (%)	9.3	9.0	8.9	8.8	8.8
Cost of funds (%)	7.5	7.2	7.2	7.1	7.1
Spread (%)	1.8	1.8	1.7	1.7	1.7

Source: Company, Emkay Research

Balance Sheet					
Y/E 2026 (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	1,101	1,101	1,101	1,101	1,101
Reserves & surplus	361,467	412,155	462,640	512,995	563,871
Net worth	362,568	413,255	463,741	514,096	564,971
Borrowings	2,688,004	2,774,225	2,913,040	3,126,245	3,416,210
Other liabilities & prov.	88,694	63,577	64,186	64,802	65,424
Total liabilities & equity	3,139,266	3,251,057	3,440,966	3,705,143	4,046,605
Net loans	2,985,190	3,115,170	3,311,547	3,577,325	3,911,966
Investments	-	-	-	-	-
Cash, other balances	14,045	12,781	8,777	10,444	16,938
Interest earning assets	2,999,235	3,127,951	3,320,324	3,587,769	3,928,904
Fixed assets	4,020	3,842	4,034	4,235	4,447
Other assets	136,010	119,265	116,609	113,138	113,254
Total assets	3,139,266	3,251,057	3,440,966	3,705,143	4,046,605
BVPS (Rs)	658.7	750.8	842.6	934.0	1,026.5
Adj. BVPS (INR)	658.7	750.8	842.6	934.0	1,026.5
Gross loans	3,077,320	3,207,070	3,407,064	3,677,935	4,019,070
Total AUM	3,077,320	3,207,070	3,407,064	3,677,935	4,019,070
On balance sheet	3,077,320	3,207,070	3,407,064	3,677,935	4,019,070
Off balance sheet	0	0	0	0	0
Disbursements	640,220	665,440	732,377	819,822	933,629
Disbursements growth (%)	8.6	3.9	10.1	11.9	13.9
Loan growth (%)	7.1	4.4	6.3	8.0	9.4
AUM growth (%)	7.3	4.2	6.2	8.0	9.3
Borrowings growth (%)	7.2	3.2	5.0	7.3	9.3
Book value growth (%)	15.5	14.0	12.2	10.9	9.9

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E 2026	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	5.3	5.1	4.8	4.6	4.2
P/B (x)	0.8	0.7	0.6	0.6	0.5
P/ABV (x)	0.8	0.7	0.6	0.6	0.5
P/PPOP (x)	0.0	0.0	0.0	0.0	0.0
Dividend yield (%)	1.9	1.9	3.1	4.4	5.9
Dupont-RoE split (%)					
NII/avg AUM	2.7	2.7	2.7	2.8	2.8
Other income	0.1	0.2	0.1	0.1	0.1
Securitization income	-	-	-	-	-
Opex	0.5	0.4	0.4	0.5	0.5
Employee expense	-	-	-	-	-
PPOP	2.4	2.4	2.4	2.4	2.4
Provisions	0.1	0.2	0.1	0.1	0.1
Tax expense	2.3	2.3	2.3	2.2	2.2
RoAUM (%)	1.8	1.8	1.8	1.8	1.8
Leverage ratio (x)	8.8	8.1	7.5	7.2	7.1
RoE (%)	16.0	14.4	13.5	12.9	12.6

Quarterly data					
Rs mn, Y/E Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
NII	20,647	20,447	21,047	22,218	20,755
NIM (%)	2.7	2.6	2.7	2.8	2.6
PPOP	18,283	18,729	18,961	19,006	17,774
PAT	13,599	13,539	13,840	14,974	14,883
EPS (Rs)	24.72	24.53	25.42	27.22	27.60

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
17-Jul-26	550	580	Add	Avinash Singh
17-Jul-26	550	580	Add	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 01, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 01, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 01, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)